written by Michael O’Leary
Not to be outdone by upstart Juvisync, a new study shows that long-time type 2 diabetes drug, Actos, may also have blood vessel benefits.
The small study of 52 type 2 diabetes patients, published in the October Journal of the American College of Cardiology found that patients taking pioglitazone (Actos) had reduced inflammation associated with plaque deposits in the main arteries serving the head and neck. Such deposits are thought to increase the risk of stroke. (Link to published site)
